Etrasimod

Generic Name
Etrasimod
Brand Names
Velsipity
Drug Type
Small Molecule
Chemical Formula
C26H26F3NO3
CAS Number
1206123-37-6
Unique Ingredient Identifier
6WH8495MMH
Background

Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P with no detectable activity on S1P and S1P receptors. S1P receptors are membrane-derived lysophospholipid signaling molecules that are involved in the sequestration of circulating peripheral lymphocytes in lymph nodes. Therefore, S1P recep...

Indication

Etrasimod is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

Associated Conditions
Moderately to Severely Active Ulcerative Colitis
Associated Therapies
-

Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis

First Posted Date
2024-07-26
Last Posted Date
2024-07-26
Lead Sponsor
Yale University
Target Recruit Count
96
Registration Number
NCT06521762
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Recruiting
Conditions
Interventions
First Posted Date
2024-05-03
Last Posted Date
2024-11-20
Lead Sponsor
Pfizer
Target Recruit Count
300
Registration Number
NCT06398626
Locations
🇺🇸

BI Research Center, Houston, Texas, United States

🇺🇸

Reddy GI Associates, Mesa, Arizona, United States

🇺🇸

Amicis Research Center, Valencia, California, United States

and more 10 locations

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

Recruiting
Conditions
Interventions
First Posted Date
2024-03-06
Last Posted Date
2024-12-20
Lead Sponsor
Pfizer
Target Recruit Count
260
Registration Number
NCT06294925
Locations
🇩🇪

Praxis Heil und Müller, Andernach, Germany

🇬🇧

Imperial College Healthcare NHS, London, United Kingdom

🇬🇧

University College London Hospital, London, United Kingdom

and more 26 locations

Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.

First Posted Date
2023-09-06
Last Posted Date
2024-11-15
Lead Sponsor
Pfizer
Registration Number
NCT06025227

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

First Posted Date
2023-02-17
Last Posted Date
2024-05-22
Lead Sponsor
Pfizer
Target Recruit Count
58
Registration Number
NCT05732454
Locations
🇺🇸

California Allergy and Asthma Medical Group, Los Angeles, California, United States

🇺🇸

Dr. Carolyn M. Wong, Los Angeles, California, United States

🇺🇸

Dr. Gerald Markovitz, Los Angeles, California, United States

and more 115 locations

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-03-18
Last Posted Date
2024-11-11
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT05287126
Locations
🇺🇸

Loma Linda Children's Hospital, Loma Linda, California, United States

🇺🇸

Loma Linda University Clinical Trial Center, Loma Linda, California, United States

🇺🇸

Loma Linda University Eye Institute, Loma Linda, California, United States

and more 57 locations

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2021-09-29
Last Posted Date
2024-10-29
Lead Sponsor
Pfizer
Target Recruit Count
54
Registration Number
NCT05061446
Locations
🇯🇵

NHO Hirosaki General Medical Center, Hirosaki-shi, Aomori-ken, Japan

🇯🇵

Our Lady of the Snow St. Mary's Hospital, Kurume, Fukuoka, Japan

🇯🇵

Kudo Internist Heart Clinic, Morioka-shi, Iwate-ken, Japan

and more 76 locations

Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2021-01-13
Last Posted Date
2023-10-16
Lead Sponsor
Pfizer
Target Recruit Count
42
Registration Number
NCT04706793
Locations
🇯🇵

Kojunkai Daido Clinic, Nagoya-shi, Aichi-ken, Japan

🇯🇵

Ishii Eye Clinic, Nagareyama-shi, Chiba, Japan

🇯🇵

Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan

and more 35 locations

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-12-24
Last Posted Date
2024-05-06
Lead Sponsor
Pfizer
Target Recruit Count
108
Registration Number
NCT04682639
Locations
🇺🇸

Mile Square Surgery Center, Fountain Valley, California, United States

🇺🇸

Bay Area Chest Physicians, P.A., - Pulmonary Function Test, Clearwater, Florida, United States

🇺🇸

Dothan Eyecare - Dr. Brent McKinley (OCT Procedure Only), Dothan, Alabama, United States

and more 249 locations

Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-10-29
Last Posted Date
2024-12-05
Lead Sponsor
Pfizer
Target Recruit Count
234
Registration Number
NCT04607837
Locations
🇺🇸

Tampa Bay Endoscopy Center, Tampa, Florida, United States

🇺🇸

Pulmonary and Critical Care Medicine Associates (PFT only), Lemoyne, Pennsylvania, United States

🇺🇸

Harrisburg Eye Associates (OCT only), Harrisburg, Pennsylvania, United States

and more 364 locations
© Copyright 2024. All Rights Reserved by MedPath